Immunotherapy boosts survival of advanced Hodgkin lymphoma in clinical trial

A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92%, suggesting a new standard therapy for the disease. The New England Journal of Medicine published the innovative clinical trial results.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup